Long term outcomes with Belatacept use in pancreas transplantation (TTS 2026) - Sep 17, 2026 - Abstract #P2.230; Pres time: Sep 22, 2026; 04:45 PM - 06:00 PM; Location: Hall 1-2; P2; "34 patients (EBV+) received Belatacept (2 de novo and 32 conversions) due to severe kidney dysfunction with chronic histological damage (5), CNI toxicity (15), pancreas dysfunction (4), AMR or DSA Ab (8), high cardiovascular risk (1) and a partial pancreas (1). Tacrolimus was minimized in 16 cases and discontinued in 18. Table 1 Reasons for Belatacept use With a mean f/u of 83mo, there were 17 rejection episodes (5Kid, 8Pan, 4KP) at 43mo (5-100)."
Cardiovascular • CNS Disorders • Diabetic Nephropathy • Gastrointestinal Disorder • Infectious Disease • Nephrology • Novel Coronavirus Disease • Transplantation
|
|
Pablo Uva1,2; Josefina Roses1; Julia Illanes1; Ignacio Cabrera1; Roxana Pilotti1; Fernanda Toniolo1; Eduardo Chuluyan2; Gustavo Werber1
|